The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 1, 2011, Pages 41-61

  Chan, Phylinda L S ^a   Jacqmin, Philippe ^b   Lavielle, Marc ^c   McFadyen, Lynn ^a   Weatherley, Barry ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Exprimo NV   (Belgium)

^c UNIVERSITÉ PARIS SUD   (France)

Author keywords

Maraviroc; MONOLIX; Population PKPD; SAEM; Viral dynamics

Indexed keywords

MARAVIROC; PLACEBO; VIRUS RNA;

ALGORITHM; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; BAYES THEOREM; CD4+ T LYMPHOCYTE; DATA ANALYSIS SOFTWARE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; FIRST ORDER CONDITIONAL ESTIMATION METHOD WITH INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MATHEMATICAL COMPUTING; MONOTHERAPY; MORNING DOSAGE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEQUENTIAL ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL PARAMETERS; STOCHASTIC APPROXIMATION OF THE STANDARD EXPECTATION MAXIMIZATION ALGORITHM; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION; VIRUS LOAD;

ALGORITHMS; COMPUTER SIMULATION; CYCLOHEXANES; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; SOFTWARE; TRIAZOLES; VIRAL LOAD;

EID: 79551612335     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-010-9175-z     Document Type: Article

References (31)

1. A Wood D Armour 2005 The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS Prog Med Chem 43 239 271 1:CAS:528:DC%2BD2MXps1Citbg%3D 10.1016/S0079-6468(05)43007-6 15850827
2. G Fätkenheuer, et al. 2005 Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 Nat Med 11 11 1170 1172 10.1038/nm1319 16205738
3. AS Perelson, et al. 1997 Decay characteristics of HIV-1-infected compartments during combination therapy Nature 387 6629 188 191 1:CAS:528:DyaK2sXjtF2gt7c%3D 10.1038/387188a0 9144290
4. S Bonhoeffer, et al. 1997 Virus dynamics and drug therapy Proc Natl Acad Sci USA 94 13 6971 6976 1:CAS:528:DyaK2sXktF2qs7w%3D 10.1073/pnas.94.13.6971 9192676
5. GA Funk, et al. 2001 Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells J Acquir Immune Defic Syndr 26 5 397 404 1:STN:280:DC%2BD3Mzis1Gmtw%3D%3D 11391158
6. MC Rosario, et al. 2005 A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc Clin Pharmacol Ther 78 5 508 519 1:CAS:528:DC%2BD2MXht1OltLbN 10.1016/j.clpt.2005.07.010 16321617
7. MC Rosario, et al. 2006 A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc J Acquir Immune Defic Syndr 42 2 183 191 1:CAS:528:DC%2BD28XltlKqs7c%3D 10.1097/01.qai.0000220021. 64115.37 16639345
8. Beal SL, Sheiner LB, Boeckmann AJ (1989-2006) NONMEM users guides, icon development solutions, Ellicott City, MD, USA
9. SL Beal LB Sheiner 1982 Estimating population kinetics Crit Rev Biomed Eng 8 3 195 222 1:STN:280:DyaL3s%2Flt1arsA%3D%3D 6754254
10. M Lindstrom D Bates 1990 Nonlinear mixed-effects models for repeated measure data Biometrics 46 673 687 1:STN:280:DyaK3M%2FlsFSktA%3D%3D 10.2307/2532087 2242409
11. X Pandhard A Samson 2009 Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects Biostatistics 10 1 121 135 10.1093/biostatistics/kxn020
12. RJ Bauer S Guzy C Ng 2007 A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples AAPS J 9 1 E60 E83 10.1208/aapsj0901007 17408237
13. MONOLIX 2.4 User Guide, vol. http://software.monolix.org. Accessed Oct 2010
14. E Kuhn M Lavielle 2005 Maximum likelihood estimation in nonlinear mixed effects models Comput Stat Data Anal 49 1020 1038 10.1016/j.csda.2004.07.002
15. B Gruzdev, et al. 2003 A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects AIDS 17 17 2487 2494 1:CAS:528:DC%2BD3sXoslWluro%3D 10.1097/00002030-200311210-00011 14600520
16. E DeJesus, et al. 2006 Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients J Acquir Immune Defic Syndr 43 1 1 5 1:CAS:528:DC%2BD28XosFGmtr8%3D 10.1097/01.qai.0000233308.82860.2f 16936557
17. D Schurmann, et al. 2007 Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults AIDS 21 10 1293 1299 10.1097/QAD.0b013e3280f00f9f 17545705
18. Golden PL et al (2007) In vitro antiviral potency and preclinical pharmacokinetics of GSK364735 predict clinical efficacy in a phase 2a study. Poster H-1047, The 47th interscience conference on antimicrobial agents and chemotherapy (ICAAC). http://img.thebody.com/confs/icaac2007/pdfs/H-1047- 306%20Golden%20ICAAC%202007.pdf. Accessed Oct 2010
19. NH Holford LB Sheiner 1981 Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models Clin Pharmacokinet 6 6 429 453 1:CAS:528:DyaL38XivVWhuw%3D%3D 10.2165/00003088- 198106060-00002 7032803
20. P Jacqmin L McFadyen JR Wade 2010 Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling J Pharmacokinet Pharmacodyn 37 2 157 177 1:CAS:528:DC%2BC3cXltlyruro%3D 10.1007/s10928-010-9151- 7 20204473
21. LB Sheiner SL Beal 1981 Some suggestions for measuring predictive performance J Pharmacokinet Biopharm 9 4 503 512 1:STN:280: DyaL38%2FnslGruw%3D%3D 10.1007/BF01060893 7310648
22. L Lindbom J Ribbing EN Jonsson 2004 Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming Comput Methods Programs Biomed 75 2 85 94 10.1016/j.cmpb.2003.11.003 15212851
23. Girard P, Mentré F (16-17 June 2005) A comparison of estimation methods in nonlinear mixed effects models using a blind analysis. Abstract 834. http://www.page-meeting.org/default.asp?id=26&keuze=abstract-view&goto= abstracts&orderby=author&abstract-id=834. Accessed Oct 2010
24. M Lavielle F Mentré 2007 Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software J Pharmacokinet Pharmacodyn 34 2 229 249 1:CAS:528:DC%2BD2sXjs1ektb8%3D 10.1007/s10928-006-9043-z 17211713
25. A Samson M Lavielle F Mentré 2006 Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model Comput Stat Data Anal 51 1562 1574 10.1016/j.csda.2006.05.007
26. AVM Herz, et al. 1996 Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay Proc Natl Acad Sci USA 93 14 7247 7251 1:CAS:528:DyaK28Xkt1WgsLk%3D 10.1073/pnas.93.14.7247 8692977
27. X Wei, et al. 1995 Viral dynamics in human immunodeficiency virus type 1 infection Nature 373 6510 117 122 1:CAS:528:DyaK2MXjtFSrt70%3D 10.1038/373117a0 7529365
28. DD Ho, et al. 1995 Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection Nature 373 6510 123 126 1:CAS:528:DyaK2MXjtFSrt7o%3D 10.1038/373123a0 7816094
29. MA Nowak, et al. 1995 HIV results in the frame: results confirmed Nature 375 6528 193 1:STN:280:DyaK2M3msFSrug%3D%3D 10.1038/375193a0 7746311
30. L Zhang SL Beal LB Sheiner 2003 Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods J Pharmacokinet Pharmacodyn 30 6 405 416 1:CAS:528:DC%2BD2cXlvFagug%3D%3D 10.1023/B:JOPA.0000012999.36063.4e 15000422
31. L Zhang SL Beal LB Sheiner 2003 Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance J Pharmacokinet Pharmacodyn 30 6 387 404 10.1023/B:JOPA.0000012998.04442.1f 15000421